Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 6/20 | 0.45 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.42 |
| ▸ | SUV39H2 | Q9H5I1 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 1/20 | 0.40 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.40 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.40 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | PTAFR | P25105 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5649910 | 0.91 | FLT3 (0.42) | FLT3BRD4KMT2A | |
| SCHEMBL5653312 | 0.90 | FLT3 (0.46) | FLT3KDM4E | |
| SCHEMBL5652607 | 0.89 | FLT3 (0.45) | FLT3 | |
| SCHEMBL5651507 | 0.88 | FLT3 (0.45) | FLT3 | |
| SCHEMBL5653197 | 0.88 | PRMT5 (0.48) | KDM4EALDH1A1POLBMEN1KMT2A | |
| SCHEMBL5651998 | 0.86 | FLT3 (0.45) | FLT3LRRK2SUV39H2BRD4POLB | |
| SCHEMBL5651707 | 0.84 | CYP2D6 (0.59) | CDK2ALDH1A1MEN1KMT2A | |
| SCHEMBL5651885 | 0.84 | FLT3 (0.45) | FLT3CDK2IKBKEAURKBTBK1 | |
| SCHEMBL5649725 | 0.84 | FLT3 (0.46) | FLT3LRRK2SUV39H2BRD4ALDH1A1 | |
| SCHEMBL5651321 | 0.82 | FLT3 (0.46) | FLT3LRRK2SUV39H2BRD4ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7220769-B2 | Azolylbenzamides and analogues and their use for treating osteoporosis | NIKEM RESEARCH S.R.L. (IT) | 2007-05-22 | — | — | US | disclosed |
| US-20050038095-A1 | Azolylbenzamides and analogues and their use for treating osteoporosis | 3-V BIOSCIENCES, INC. | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038095-A1 | Azolylbenzamides and analogues and their use for treating osteoporosis | NR0B2, NR0B1, NCOR1 | FLT3 1968/4885LRRK2 2726/4885SUV39H2 304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.